SCHEMBL782244

SCHEMBL782244

CCOC(OCC)(OCC)C(C)O

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.36
TSHR P16473 3/20 0.35
LMNA P02545 1/20 0.32
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1286179 0.75 LMNA (0.35) LMNA
SCHEMBL30366434 0.74
SCHEMBL6326337 0.74 ALOX15 (0.32)
SCHEMBL7642240 0.72
SCHEMBL15903664 0.72
SCHEMBL27691751 0.72 THRB (0.36) LMNA
SCHEMBL10583744 0.71 FDPS (0.31)
SCHEMBL27537930 0.71 LMNA (0.32) LMNA
SCHEMBL1544663 0.71 LMNA (0.32) LMNA
SCHEMBL10727644 0.71 LMNA (0.32) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960535-B1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HOUSEY GERARD M (US) 2024-05-08 EP disclosed
US-20240125769-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2024-04-18 US disclosed
US-11714080-B2 Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC (US) 2023-08-01 US disclosed
US-11692998-B2 Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC (US) 2023-07-04 US disclosed
US-20210215670-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2021-07-15 US disclosed
US-20210215671-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2021-07-15 US disclosed
US-10955408-B2 Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC (US) 2021-03-23 US disclosed
US-20200049693-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2020-02-13 US disclosed
US-10473643-B2 Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC (US) 2019-11-12 US disclosed
US-20180356395-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2018-12-13 US disclosed
CN-101296912-B Theramutein modulators HOUSEY GERARD M 2012-07-04 CN disclosed
CN-102459249-A Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases EXELIXIS INC 2012-05-16 CN disclosed
US-20120071680-A1 SURFACE-MODIFIED ZIRCONIA NANOCRYSTAL PARTICLE AND METHOD FOR PRODUCING SAME HOYA CORPORATION (JP) 2012-03-22 US disclosed
US-20100016298-A1 Theramutein modulators HOUSEY GERAD M 2010-01-21 US disclosed
US-20090275070-A1 Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators HOUSEY GERARD M 2009-11-05 US disclosed
CN-101370944-A Compounds and methods for identifying, synthesizing, optimizing and characterizing protein modulators HOUSEY GERARD M (US) 2009-02-18 CN disclosed
CN-101296912-A Theramutein modulators HOUSEY GERARD M (US) 2008-10-29 CN disclosed
US-20070111199-A1 Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC 2007-05-17 US disclosed
US-4847229-A Process for hydroformylation of unsaturated compounds using iron carbonyl catalysts THE DOW CHEMICAL COMPANY (US) 1989-07-11 US disclosed
US-4782188-A Process for hydroformylation of unsaturated compounds using iron carbonyl catalysts THE DOW CHEMICAL COMPANY (US) 1988-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016298-A1 Theramutein modulators TSG101, SERPINE1, PLAUR MAPK1 2381/4885TSHR 2353/4885LMNA 2028/4885
US-20120071680-A1 SURFACE-MODIFIED ZIRCONIA NANOCRYSTAL PARTICLE AND METHOD FOR PRODUCING SAME PIM1, NOXO1, PIM3 MAPK1 2793/4885TSHR 2214/4885LMNA 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.